AU2023216333A1 - Combination therapy for use in treatment of non-small cell lung cancer. - Google Patents

Combination therapy for use in treatment of non-small cell lung cancer. Download PDF

Info

Publication number
AU2023216333A1
AU2023216333A1 AU2023216333A AU2023216333A AU2023216333A1 AU 2023216333 A1 AU2023216333 A1 AU 2023216333A1 AU 2023216333 A AU2023216333 A AU 2023216333A AU 2023216333 A AU2023216333 A AU 2023216333A AU 2023216333 A1 AU2023216333 A1 AU 2023216333A1
Authority
AU
Australia
Prior art keywords
approximately
dose
treatment
antigen binding
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023216333A
Other languages
English (en)
Inventor
Mario Filion
Jacques Jolivet
Julie Laurin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alethia Biotherapeutics ULC
Original Assignee
Alethia Biotherapeutics ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alethia Biotherapeutics ULC filed Critical Alethia Biotherapeutics ULC
Publication of AU2023216333A1 publication Critical patent/AU2023216333A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2023216333A 2022-02-07 2023-02-06 Combination therapy for use in treatment of non-small cell lung cancer. Pending AU2023216333A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263307533P 2022-02-07 2022-02-07
US63/307,533 2022-02-07
US202263333597P 2022-04-22 2022-04-22
US63/333,597 2022-04-22
PCT/CA2023/050151 WO2023147673A1 (en) 2022-02-07 2023-02-06 Combination therapy for use in treatment of non-small cell lung cancer

Publications (1)

Publication Number Publication Date
AU2023216333A1 true AU2023216333A1 (en) 2024-08-22

Family

ID=87553087

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023216333A Pending AU2023216333A1 (en) 2022-02-07 2023-02-06 Combination therapy for use in treatment of non-small cell lung cancer.

Country Status (9)

Country Link
US (1) US20250108110A1 (cg-RX-API-DMAC7.html)
EP (1) EP4475885A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025505652A (cg-RX-API-DMAC7.html)
KR (1) KR20240153627A (cg-RX-API-DMAC7.html)
AU (1) AU2023216333A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243096A1 (cg-RX-API-DMAC7.html)
IL (1) IL314600A (cg-RX-API-DMAC7.html)
MX (1) MX2024009671A (cg-RX-API-DMAC7.html)
WO (1) WO2023147673A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2928846A1 (en) * 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
CA2862739A1 (en) * 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
EP4329801A4 (en) * 2021-04-27 2025-05-14 Alethia Biotherapeutics Inc. Method for allowing immune cells infiltration in tumors

Also Published As

Publication number Publication date
IL314600A (en) 2024-09-01
WO2023147673A1 (en) 2023-08-10
CA3243096A1 (en) 2023-08-10
MX2024009671A (es) 2024-08-19
EP4475885A4 (en) 2026-02-18
JP2025505652A (ja) 2025-02-28
KR20240153627A (ko) 2024-10-23
EP4475885A1 (en) 2024-12-18
US20250108110A1 (en) 2025-04-03

Similar Documents

Publication Publication Date Title
CA2638040A1 (en) Treatment of metastatic breast cancer
KR20180101584A (ko) 항-pd-1 항체 및 또 다른 항암제의 조합을 사용하는 폐암의 치료
JP2021513541A (ja) 抗pd−1抗体によるがんの処置方法
US20240317884A1 (en) Method for allowing immune cells infiltration in tumors
WO2012119077A1 (en) Co -administration of eribulin and farletuzumab for the treatment of breast cancer
JP2022512866A (ja) がんを処置するための抗lag3抗体の投薬レジメンおよび抗pd-1抗体との組み合わせ治療
CN103945866A (zh) 与帕利他赛组合的抗ErbB3抗体用于治疗妇科癌症
AU2023308189A1 (en) Combination therapy
WO2012177440A1 (en) Dosage and administration of anti-erbb3 antibodies in combination with paclitaxel
EP4308243A1 (en) Methods for treating cancer with anti-ilt3 antibodies
US20250108110A1 (en) Combination therapy for use in treatment of non-small cell lung cancer
KR20250115399A (ko) 항-ddr1 항체를 사용한 암 치료 방법
CN118900700A (zh) 用于治疗非小细胞肺癌的联合疗法
US20260116977A1 (en) Methods of treating melanoma using an anti-ctla4 antibody
KR20250116698A (ko) Dll3-발현 암의 치료 방법
KR20240170820A (ko) 고형 종양의 치료

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: TO AMEND THE APPLICANT NAME TO ALETHIA BIOTHERAPEUTICS ULC